Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000325114 | SCV000338173 | uncertain significance | not provided | 2015-12-18 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000325114 | SCV003817915 | uncertain significance | not provided | 2019-07-16 | criteria provided, single submitter | clinical testing | |
Genome |
RCV000509199 | SCV000607090 | not provided | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. | |
Prevention |
RCV004737398 | SCV005359336 | uncertain significance | PLEC-related disorder | 2024-08-31 | no assertion criteria provided | clinical testing | The PLEC c.6062T>C variant is predicted to result in the amino acid substitution p.Leu2021Pro. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0021% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |